Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2008

01-02-2008 | Original Paper

On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands

Authors: W. J. Louwman, A. C. Voogd, J. A. A. M. van Dijck, G. A. P. Nieuwenhuijzen, J. Ribot, J. F. M. Pruijt, J. W. W. Coebergh

Published in: Cancer Causes & Control | Issue 1/2008

Login to get access

Abstract

Background

Much progress has been made in the early diagnosis and treatment of breast cancer. We have assessed the changing burden of this disease, by means of a comprehensive description of trends in incidence, survival, and mortality.

Methods

Data on breast cancer patients diagnosed between 1975 and 2004 (n = 26,464) registered in the population-based Eindhoven Cancer Registry were investigated.

Results

Incidence for patients aged below 40 and 40–49 has increased by 2.1% and 2.4% annually, since 1995 (p = 0.08 and p = 0.001, respectively). Mortality decreased in all age groups, but most markedly among women aged 50–69 (−1.5% yearly since 1985, p = 0.14). The proportion of stage I tumors increased from 25% to 39%, that of advanced stages (III & IV) decreased from 30% (1975–1984) to 13% in 1995–2004, and the proportion of in situ tumors increased from 1.5% to 10%. Adjuvant systemic treatment was administered to 15% of patients in 1975–1984 vs. 49% in 1995–2004. Relative 10-year survival rates for women aged 50–69 (period analysis) increased from 53% to 75% between 1975 and 2004. The best prognosis was observed for women aged 45–54. Women younger than 35 had a particularly poor prognosis.

Conclusion

The observed improvement in survival of breast cancer patients during the last three decades is impressive. The peak in breast cancer incidence is not yet in sight considering the recent trends in exposure to known risk factors and improved diagnosis. The combination of increasing incidence and improved survival rates implies that the number of prevalent cases will continue to increase considerably in the next 10 years.
Literature
1.
Ferlay J, Bray F, Pisani P, Parkin DM (2002) GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide, 5.2 edn. IARC Press, Lyon
2.
Tyczynski JE, Plesko I, Aareleid T, Primic-Zakelj M, Dalmas M, Kurtinaitis J, Stengrevics A, Parkin DM (2004) Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer 112:1056–1064PubMedCrossRef
3.
Bray F, Sankila R, Ferlay J, Parkin DM (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38:99–166PubMedCrossRef
4.
Ferlay J, Bray F, Sankila R, Parkin DM (1999) EUCAN: Cancer incidence, mortality and prevalence in the European Union 1998, 5.0 edn. IARC, Lyon
5.
6.
Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229–239PubMedCrossRef
7.
Nab HW, Hop WC, Crommelin MA, Kluck HM, van der Heijden LH, Coebergh JW (1994) Changes in long term prognosis for breast cancer in a Dutch cancer registry. BMJ 309:83–86PubMed
8.
Nab HW, Hop WC, Crommelin MA, Kluck HM, Coebergh JW (1994) Improved prognosis of breast cancer since 1970 in south-eastern Netherlands. Br J Cancer 70:285–288PubMed
9.
Louwman WJ, van Diest PJ, van Beek MW, Schapers RF, Nolthenius-Puylaert TM, Baak JP, Coeberg JW (2002) Trends in breast cancer aggressiveness before the introduction of mass screening in southeastern Netherlands 1975–1989. Breast Cancer Res Treat 73:199–206PubMedCrossRef
10.
Janssen-Heijnen MLG, Louwman WJ, van de Poll-Franse LV, Coebergh JWW (2005) Results of 50 years cancer registry in the South of the Netherlands: 1955–2004 (in Dutch). Eindhoven Cancer Registry, Eindhoven
11.
Botha JL, Bray F, Sankila R, Parkin DM (2003) Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 39:1718–1729PubMedCrossRef
12.
Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F (2006) Should we use incidence, survival or mortality to assess breast cancer trends in European women? Nat Clin Pract Oncol 3:228–229PubMedCrossRef
13.
Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents, vol VIII. IARC Scientific Publications, Lyon
14.
Harmer MH (1978) TNM classification of malignant tumors, 3rd edn. IUCC, Geneva
15.
Hermanek P, Sobin L (1992) TNM classification of malignant tumors, 4th edn, 2nd rev. edn. Springer-Verlag, Berlin
16.
Sobin LH, Wittekind C (1997) UICC international union against cancer. TNM classification of malignant tumours, 5th edn. Wiley-Liss, Geneva, Switzerland, p 227
17.
Sobin LH, Wittekind C (2002) UICC International Union against Cancer. TNM classification of malignant tumours, 6th edn. Wiley-Liss, Geneva, Switzerland, p 239
18.
Voogd AC, van Beek MW, Crommelin MA, Kluck HM, Repelaer van Driel OJ, Coebergh JW (1994) Management of early breast cancer in southeast Netherlands since 1984. A population-based study. Regional Breast Cancer Study Group. Acta Oncol 33:753–757PubMedCrossRef
19.
Rutgers EJ, Nortier JW, Tuut MK, van Tienhoven G, Struikmans H, Bontenbal M, von Meyenfeldt MF, Vreugdenhil G, Benraadt T, Garssen B, Peterse JL (2002) Dutch institute for healthcare improvement guideline, “Treatment of breast cancer”. Ned Tijdschr Geneeskd 146:2144–2151PubMed
20.
Clayton D, Schifflers E (1987) Models for temporal variation in cancer rates. I: age-period and age-cohort models. Stat Med 6:449–467PubMedCrossRef
21.
Hakulinen T, Abeywickrama KH (1985) A computer program package for relative survival analysis. Comput Programs Biomed 19:197–207PubMedCrossRef
22.
Houterman S, Janssen-Heijnen ML, van de Poll-Franse LV, Brenner H, Coebergh JW (2006) Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol 17:709–712PubMedCrossRef
23.
Brenner H, Gefeller O (1996) An alternative approach to monitoring cancer patient survival. Cancer 78:2004–2010PubMedCrossRef
24.
van Dijck JA, Hendriks JH, Holland R, Schouten LJ, Verbeek AL (2000) Alterations of stage distribution for breast cancer since the implementation of national screening program in the Netherlands during 1989–1995. Ned Tijdschr Geneeskd 144:1119–1124PubMed
25.
Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL, de Koning HJ (2004) Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 91:861–867PubMed
26.
Hankinson SDH (2002) Breast cancer. In: Adami HO, Hunter DDT (eds) Textbook of cancer epidemiologyed. Oxford Univeristy Press, Oxford, pp 301–339
27.
28.
SignaleringscommissieKanker, De rol van voeding bij het ontstaan van kanker. KWF Kankerbestrijding (2004)
29.
SignaleringscommissieKanker, De rol van lichaamsbeweging bij preventie van kanker. KWF Kankerbestrijding (2005)
30.
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674PubMedCrossRef
31.
Robbins AS, Clarke CA (2007) Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25:3437–3439PubMedCrossRef
32.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. Jama 288:321–33PubMedCrossRef
33.
Soerjomataram I, Louwman MW, Visser O, Van Leeuwen FE, Coebergh JW (2007) Does the decrease in hormone-replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 25:5038–5039PubMedCrossRef
34.
Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K (2004) Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 48:39–49PubMedCrossRef
35.
van Duijnhoven FJ, van Gils CH, Bezemer ID, Peeters PH, van der Schouw YT, Grobbee DE (2006) Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. Maturitas 53:462–475PubMedCrossRef
36.
Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C (2004) Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960. Int J Cancer 110:155–169PubMedCrossRef
37.
Levi F, Lucchini F, Negri E, La Vecchia C (2004) Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 101:2843–2850PubMedCrossRef
38.
Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, Verbeek AL, de Koning HJ (2003) Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361:1411–1417PubMedCrossRef
39.
40.
Welch HG, Schwartz LM, Woloshin S (2000) Are increasing 5-year survival rates evidence of success against cancer? Jama 283:2975–2978PubMedCrossRef
41.
Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ (2004) Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 91:242–247PubMed
42.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef
43.
Thomson CS, Brewster DH, Dewar JA, Twelves CJ (2004) Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur J Cancer 40:743–753PubMedCrossRef
44.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy, hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
45.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583PubMedCrossRef
46.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365PubMedCrossRef
47.
Siesling S, van de Poll-Franse LV, Jobsen JJ, Repelaer van Driel OJ, Voogd AC (2005) Trends and variation in breast conserving surgery in the southeast and east of the Netherlands over the period 1990–2002. Ned Tijdschr Geneeskd 149:1941–1946PubMed
48.
Visser O, van Leeuwen FE (2005) Stage-specific survival of epithelial cancers in North-Holland/Flevoland, The Netherlands. Eur J Cancer 41:2321–2330PubMedCrossRef
49.
Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604–1608PubMedCrossRef
50.
Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563PubMedCrossRef
51.
Sant M, Capocaccia R, Verdecchia A, Esteve J, Gatta G, Micheli A, Coleman MP, Berrino F (1998) Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. The EUROCARE Working Group. Int J Cancer 77:679–683PubMedCrossRef
52.
Mohle-Boetani J, Grosser S, Malec M, Whittemore AS (1986) Survival advantage among patients with breast cancer diagnosed at 45 to 49 years of age. N Engl J Med 315:587PubMed
53.
Holli K, Isola J (1997) Effect of age on the survival of breast cancer patients. Eur J Cancer 33:425–428PubMedCrossRef
54.
Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474–478PubMedCrossRef
55.
SignaleringscommissieKanker, Kanker in Nederland. Trends, prognoses en implicaties voor zorgvraag. KWF Kankerbestrijding (2004)
Metadata
Title
On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands
Authors
W. J. Louwman
A. C. Voogd
J. A. A. M. van Dijck
G. A. P. Nieuwenhuijzen
J. Ribot
J. F. M. Pruijt
J. W. W. Coebergh
Publication date
01-02-2008
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9075-8

Other articles of this Issue 1/2008

Cancer Causes & Control 1/2008 Go to the issue

Original Paper

Availability and utility of body mass index for population-based cancer surveillance

Original Paper

Temporal patterns of association between cigarette smoking and leukemia risk

Original Paper

Plasma folate and risk of colorectal cancer in a nested case-control study: the Japan Public Health Center-based prospective study

Original Paper

Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices

Original Paper

Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study); with special focus on cholelithiasis, body mass index, and their effect modification

Original Paper

Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits